Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca B Regulatory News (SVCT)

Share Price Information for Seneca B (SVCT)

Share Price is delayed by 15 minutes
Get Live Data
44.00    0.00 (0.00%)
Bid:
43.00
Ask:
45.00
Spread: 2.00 (4.651%)
Market Cap: £14.56m
SVCT Live PriceLast checked at - London Stock Exchange

Intraday Seneca B Share Chart

Directorate Change

9 Dec 2019 17:45



Directorate Change

Seneca Growth Capital VCT Plc (the “Company”)

9 December 2019

Appointment of Director

As envisaged in the Company’s Annual Report, which was published in April 2019, the Company has carried out a search for a further Non-Executive Director and is pleased to announce the appointment of Alex Clarkson to the Board and to the Audit Committee with effect from 9 December 2019.

Alex is a Managing Director of Bamburgh Capital. He qualified as a chartered accountant with PricewaterhouseCoopers in 1998, joined Brewin Dolphin Securities in 2000 before becoming co-founder of Zeus Capital in 2003. Alex then went on to co-found Bamburgh Capital in 2011, executing over 20 transactions acting on both the “buy” and “sell” side and raising funding. During this time, Alex was co-founder of Compass BioScience Group Limited and Collbio, two highly acquisitive companies, and became interim CFO of Collbio which undertook an IPO on the London Stock Market within an 18-month period, changing its name to Collagen Solutions.

Alex will stand for re-election by shareholders at the Annual General Meeting of the Company to be held in 2020. In relation to this appointment, there is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 R.

The Board now consists of four Directors comprising two Independent Directors who were appointed prior to the appointment of Seneca Partners Limited (‘the Manager’), Richard Manley, who is the representative of the Manager and Alex Clarkson, who is the third Independent Director. Notwithstanding that the Company is listed, it is one of the smallest by market value at present and is, therefore, not strictly subject to the recommendations of the Hampton-Alexander Report in respect of diversity. However, the Board fully supports the aims of that Report and intends to make further appointments to the Board in due course and will, over time, strive to comply with these recommendations.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk


Date   Source Headline
4th Jun 20261:34 pmRNSResults of Annual General Meeting voting
30th Apr 202612:12 pmRNSAnnual Report, Notice of AGM and new NAVs
20th Mar 20264:36 pmRNSUnaudited Net asset value (“NAV”) Update
28th Nov 202512:06 pmRNSShare Buy-back and Total Voting Rights
11th Nov 202512:11 pmRNSSecond Interim Dividend on B Shares
21st Oct 20252:40 pmRNSPDMR Shareholding
15th Oct 20254:26 pmRNSUpdated NAV & Ordinary Share Class Dividend
26th Sep 20251:50 pmRNSUnaudited Half-year Report for 6m to 30 June 2025
8th Aug 20254:05 pmRNSIssue of Equity and Total Voting Rights
2nd Jun 20253:15 pmRNSShare Buy-back and Total Voting Rights
22nd May 20251:20 pmRNSResult of AGM
12th May 20254:02 pmRNSInterim Capital Dividend on Ordinary Shares
7th May 20253:04 pmRNSIssue of Equity and Total Voting Rights
29th Apr 20253:58 pmRNSIssue of Supplementary Prospectus
23rd Apr 20254:15 pmRNSFinal results and Notice of AGM
4th Apr 20253:37 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20257:00 amRNSNet Asset Value(s)
19th Mar 20257:00 amRNSInterim Dividend on B Shares
11th Dec 20242:44 pmRNSDirector/PDMR Dealing
11th Dec 20242:39 pmRNSIssue of Equity and Total Voting Rights
15th Nov 20243:15 pmRNSShare Buy-back and Total Voting Rights
14th Nov 20243:32 pmRNSSecond Interim Dividend on B Shares
16th Oct 20247:00 amRNSNet Asset Value(s)
12th Sep 20242:11 pmRNSOffer for Subscription and Prospectus Publication
9th Aug 20243:20 pmGNWIssue of Equity and Total Voting Rights
6th Aug 202410:10 amGNWClosure of Offer for Subscription
25th Jul 20247:00 amGNWHalf-year Report
15th May 202412:16 pmGNWResult of AGM
1st May 20243:34 pmGNWIssue of Equity and Total Voting Rights
1st May 20247:00 amGNWB Share Net Asset Value
22nd Apr 202410:46 amGNWShare Buy-back and Total Voting Rights
5th Apr 202412:44 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20247:00 amGNWNet Asset Value(s)
28th Mar 202412:11 pmGNWIssue of Supplementary Prospectus
22nd Mar 20247:00 amGNWFinal Results, Notice of AGM, Updated NAV
7th Mar 20247:00 amGNWInterim Dividend on B Shares
19th Feb 20244:36 pmGNWDirector Declaration
21st Dec 202312:03 pmGNWIssue of Equity and Total Voting Rights
6th Dec 20233:24 pmGNWDirector/PDMR Dealing
6th Dec 20233:14 pmGNWIssue of Equity and Total Voting Rights
29th Nov 202312:36 pmGNWChange of the Company’s Auditor
20th Nov 20233:20 pmGNWB Share Buy-back and Total Voting Rights
3rd Nov 20237:00 amGNWDividend Declaration
12th Oct 20237:00 amGNWNet Asset Value(s)
11th Oct 20233:39 pmGNWDirectorate Change
24th Aug 20234:18 pmGNWOffer for Subscription and Publication of Prospectus
18th Aug 20235:08 pmGNWIssue of Equity and Total Voting Rights and Capital Reorganisation
2nd Aug 202311:40 amGNWHalf-year Report
30th Jun 20231:58 pmGNWIssue of Equity and Total Voting Rights
20th Jun 20238:50 amGNWShare Buy-back and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.